Anebulo Pharmaceuticals Advances Pediatric Cannabis Toxicity Treatment with Oral Selonabant Success
- Anebulo Pharmaceuticals completed a Phase 2 study showing oral selonabant's efficacy against pediatric cannabis toxicity.
- The FDA is collaborating with Anebulo to expedite the development of intravenous selonabant for acute cannabis toxicity.
- Anebulo raised $15 million to support the development of selonabant, addressing pediatric cannabis toxicity effectively.
Anebulo Pharmaceuticals Advances Pediatric Cannabis Toxicity Treatment
Anebulo Pharmaceuticals, Inc. announces a significant stride in addressing pediatric cannabis toxicity with the completion of a Phase 2 proof-of-concept study demonstrating the efficacy of oral selonabant in countering the central nervous system effects of delta-9-tetrahydrocannabinol (THC). This study involved 134 adult participants and has paved the way for Anebulo’s future development of intravenous selonabant as a targeted therapy for acute cannabis-induced toxicity, particularly in children. The success of this clinical trial is particularly relevant given the increasing prevalence of cannabis use among minors, raising concerns about potential toxicity and the lack of effective treatments available.
In light of these promising results, Anebulo actively engages with the U.S. Food and Drug Administration (FDA). The agency recognizes the urgent need for effective treatments to combat pediatric cannabis toxicity and is open to collaborating closely with Anebulo to expedite the development of selonabant. This partnership aims to navigate the regulatory landscape efficiently, ensuring that a safe and effective treatment can be brought to market in a timely manner. Anebulo plans to initiate its Phase I Single Ascending Dose (SAD) study of intravenous selonabant in healthy adults in the first half of 2025, marking a crucial step in the clinical development process for this innovative therapy.
The company's recent capital raise further strengthens its position in the market, securing $15 million through a definitive stock purchase agreement with 22NW and other investors. This funding allows Anebulo to restructure its existing financial obligations, reducing the maximum loan size to approximately $3 million, which limits the reliance on securitization. CEO Richie Cunningham emphasizes the importance of this financing as a means to support the development of selonabant without diluting stock value. He reiterates the critical need for effective treatment options for children suffering from cannabis toxicity and highlights the comprehensive market assessment that underlines the potential of selonabant as a vital therapeutic intervention.
Anebulo's commitment to addressing the challenges posed by pediatric cannabis toxicity is underscored by its strategic initiatives and collaborations. With the FDA's support, the company aims to bring much-needed solutions to the forefront of pediatric healthcare. The advancements in the selonabant program signify a proactive approach to a growing public health concern, reflecting Anebulo's dedication to innovation in the biopharmaceutical industry.
As the company progresses, it remains focused on ensuring that its therapies reach those in need, marking Anebulo Pharmaceuticals as a key player in the evolving landscape of cannabinoid-related treatments.